{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T15:11:27Z","timestamp":1780672287996,"version":"3.54.1"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare and highly aggressive lymphoma with a dismal prognosis and no established standard therapy. Its frequent expression of BCL-2 provides a rationale for targeting this anti-apoptotic protein.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We report the case of a 34-year-old female with refractory MEITL who failed prior lines of therapy, including CHOPE and gemcitabine\/oxaliplatin (GemOx) combined with golidocitinib. Based on positive BCL-2 expression by immunohistochemistry, a salvage regimen combining venetoclax with Gemox was administered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The treatment induced a rapid and significant clinical improvement. A follow-up PET\/CT scan confirmed complete metabolic remission. The main adverse event was grade 4 neutropenia and thrombocytopenia with febrile neutropenia, attributable primarily to the Gemox backbone, which resolved with supportive care. The off-label use was approved by the institutional committee, and informed consent was obtained.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>To our knowledge, this is the first report of successful treatment of refractory MEITL with a venetoclax-containing regimen. This case validates BCL-2 as a actionable therapeutic target in MEITL. Future efforts should focus on optimizing combination partners for venetoclax to improve efficacy and tolerability. The rationale for exploring venetoclax as post-transplant maintenance therapy in MEITL is also discussed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1710764","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:22:41Z","timestamp":1770355361000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Targeting the Achilles\u2019 heel of monomorphic epitheliotropic intestinal T-cell lymphoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Song","family":"Xue","sequence":"first","affiliation":[{"name":"Lu Daopei Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-fei","family":"Gu","sequence":"additional","affiliation":[{"name":"Hexiaoduo Beijing Health Management Co., Ltd","place":["Beijing, China"]},{"name":"Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Department of Hematology, Tongji Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[{"name":"Lu Daopei Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Lu Daopei Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Lu Daopei Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-peng","family":"Sun","sequence":"additional","affiliation":[{"name":"Lu Daopei Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-yu","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplant, Hebei Yanda Lu Daopei Hospital","place":["Langfang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03791-y","article-title":"Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma","volume":"98","author":"Yi","year":"2019","journal-title":"Ann Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(25)00073-0","article-title":"Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee","volume":"12","author":"Damaj","year":"2025","journal-title":"Lancet Haematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021788","article-title":"Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL)","volume":"144","author":"Marchi","year":"2024","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281226","article-title":"Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome","volume":"108","author":"Veloza","year":"2023","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2024.152293","article-title":"From the archives of MD Anderson Cancer Center: Monomorphic epitheliotropic intestinal T-cell lymphoma: A case with an unusual immunophenotype and discussion of differential diagnosis","volume":"70","author":"Dcunha","year":"2024","journal-title":"Ann Diagn Pathol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s40001-024-01797-5","article-title":"Clinicopathological and molecular genetic alterations in monomorphic-epitheliotropic intestinal T-cell lymphoma of the small intestine","volume":"29","author":"Zhou","year":"2024","journal-title":"Eur J Med Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1089\/pmr.2022.0011","article-title":"Palliative radiation therapy without chemotherapy for a patient with monomorphic epitheliotropic intestinal T cell lymphoma: A case report","volume":"3","author":"Kusada","year":"2022","journal-title":"Palliat Med Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances","article-title":"Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy","volume":"4","author":"Voorhees","year":"2020","journal-title":"Blood Adv"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e72169","DOI":"10.7759\/cureus.72169","article-title":"A case of abscessing ileocecal monomorphic epitheliotropic intestinal T-cell lymphoma","volume":"16","author":"Bekyarova","year":"2024","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqae102","article-title":"Primary intestinal T-cell and natural killer-cell lymphomas: Clinicopathologic and prognostic features of 79 cases in South China","volume":"163","author":"Guo","year":"2025","journal-title":"Am J Clin Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20160894","article-title":"Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2","volume":"214","author":"Moffitt","year":"2017","journal-title":"J Exp Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1388623","article-title":"Hematopoietic stem cell transplantation to improve prognosis in aggressive monomorphic epitheliotropic intestinal T-cell lymphoma","volume":"14","author":"Min","year":"2024","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-01987-5","article-title":"Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse","volume":"58","author":"Kent","year":"2023","journal-title":"Bone Marrow Transplant"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1710764\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:22:43Z","timestamp":1770355363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1710764\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":13,"alternative-id":["10.3389\/fonc.2026.1710764"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1710764","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"article-number":"1710764"}}